Everforth Inc quarterly report, Q1 FY2016

Business context and reporting period

On Assignment, Inc. (the registrant named in the filing; not “Everforth Inc.”) filed this unaudited Form 10-Q for the quarter ended March 31, 2016. It provides professional staffing and consulting services through its Apex and Oxford segments. Results include the 2015 acquisitions of Creative Circle and LabResource; year-over-year comparisons are therefore affected by those acquisitions.

Financial performance

MetricQ1 2016Q1 2015
Revenue$582.0 million$430.0 million
Gross profit / margin$187.8 million / 32.3%$135.9 million / 31.6%
Operating income$37.8 million$25.1 million
Interest expense, net$9.0 million$3.1 million
Income from continuing operations$17.3 million$13.0 million
Net income$17.4 million$39.1 million
Diluted earnings per share$0.32$0.75
Operating cash flow$37.3 million$19.9 million
  • Reported revenue rose 35.3%; excluding acquisition contributions, revenue grew 16.9%. On a pro forma basis, revenue increased 17.7% (18.2% at constant currency).
  • Reported gross margin expanded 70 basis points, partly because Creative Circle has higher margins. On a pro forma basis, gross margin compressed 70 basis points, mainly due to revenue mix.
  • SG&A was $139.9 million, or 24.0% of revenue, versus $105.9 million, or 24.6%. Management cited acquisition costs, higher stock compensation and incentive accruals, and investments in new practice areas; adjusted for specified items, SG&A as a share of revenue improved.
  • Net income fell chiefly because Q1 2015 included a $25.7 million after-tax gain on the sale of the Physician Segment. Continuing-operations income increased.
  • Cash increased to $28.4 million from $23.9 million at year-end. Working capital was $256.4 million. Investing activities used $1.1 million, including $7.3 million of capital spending partly offset by $6.0 million of sale proceeds. Financing activities used $31.7 million, primarily for debt repayment.

Debt, liquidity, and other key items

  • Long-term debt was $723.2 million net of deferred loan costs; gross facility borrowings were $741.0 million ($707.0 million term loan and $34.0 million revolver). The weighted-average interest rate was 3.7%.
  • The company reported a 2.80-to-1.00 funded-debt-to-EBITDA ratio, versus a maximum covenant ratio of 4.25-to-1.00 at quarter-end, and stated it was in compliance. Revolver availability was $112.5 million.
  • Management said working capital, available revolver capacity, and expected operating cash flows should cover obligations, working capital needs, and capital expenditures for the next 12 months. Of cash on hand, $10.3 million was held abroad; the company said it did not intend to repatriate it.
  • Contingent acquisition consideration was valued at $21.6 million and was expected to be paid within three months. The Physician Segment sale escrow released $6.0 million in March 2016.

Outlook, risks, and unusual items

The filing gives no specific revenue or earnings guidance. Management described stronger demand and improved sales-consultant productivity as factors supporting Apex Systems’ growth, while noting segment and consolidated margin pressure from business mix. Forward-looking risks include demand and economic conditions, recruiting and retaining consultants and professionals, client competition, growth management, systems performance, litigation, acquisition integration, and execution of the strategic plan.

Interest-rate exposure is material: the filing estimates that a 100-basis-point change in rates on $741.0 million of variable-rate debt would change annual interest expense by approximately $7.4 million. Management said a 10% foreign-currency move would not materially affect the financial statements. The company reported no interim goodwill impairment triggers and no material expected effect from pending ordinary-course legal matters.

Important facts for investors to verify

  • Confirm the issuer identity: the supplied filing is for On Assignment, Inc., despite the request metadata naming Everforth Inc.
  • Assess underlying growth using the filing’s pro forma and constant-currency figures, rather than reported growth alone, and monitor the contribution and integration of Creative Circle and LabResource.
  • Track debt reduction, floating-rate interest costs, covenant headroom, and the expected $21.6 million contingent-consideration payment.
  • Monitor whether pro forma gross-margin compression persists and whether revenue growth converts into operating cash flow.
  • Consider the prior-period Physician Segment sale gain when comparing net income and EPS.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.